Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.64 |
| ▸ | SYK | P43405 | 1/20 | 0.62 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074183 | 1.00 | CTSK (0.64) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL12220545 | 0.90 | SYK (0.69) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL25949248 | 0.89 | CTSK (0.65) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL14923444 | 0.89 | CTSK (0.62) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL5724608 | 0.89 | CTSK (0.62) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL2723504 | 0.89 | CTSK (0.62) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL13864149 | 0.88 | SYK (0.58) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL25182274 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL2724462 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL10983417 | 0.86 | CTSK (0.60) | CTSKCTSSCTSLCTSBCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | BET1, PGGT1B, RABGGTB | CTSK 2055/4885SYK 4256/4885CTSS 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.